Pomalidomide
- Generic Name
- Pomalidomide
- Brand Names
- Imnovid, Pomalyst, Imnovid (previously Pomalidomide Celgene), Pomalidomide Viatris, Pomalidomide Zentiva, Pomalidomide Krka, Pomalidomide Accord
- Drug Type
- Small Molecule
- Chemical Formula
- C13H11N3O4
- CAS Number
- 19171-19-8
- Unique Ingredient Identifier
- D2UX06XLB5
- Background
Pomalidomide, an analogue of thalidomide, is an immunomodulatory antineoplastic agent. FDA approved on February 8, 2013.
- Indication
Pomalidomide is indicated for patients with multiple myeloma who have received at least two prior therapies including lenalidomide and have demonstrated disease progression on or within 60 days of completion of the last therapy. It is also indicated for the treatment of Kaposi's sarcoma (KS) in AIDS patients who have failed highly active antiretroviral thera...
- Associated Conditions
- Kaposi's Sarcoma, Multiple Myeloma (MM)
- Associated Therapies
- -
Pomalidomide for Chronic Graft-versus-Host Disease
- Conditions
- Interventions
- First Posted Date
- 2012-09-20
- Last Posted Date
- 2019-06-18
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 34
- Registration Number
- NCT01688466
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
Carfilzomib, Pomalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2012-08-15
- Last Posted Date
- 2024-11-19
- Lead Sponsor
- University of Chicago
- Target Recruit Count
- 101
- Registration Number
- NCT01665794
- Locations
- 🇺🇸
University of Chicago Comprehensive Cancer Center, Chicago, Illinois, United States
🇨🇦University Health Network - Princess Margaret Cancer Center, Toronto, Ontario, Canada
🇺🇸University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States
Pomalidomide (POM) in Combination With Low Dose Dexamethasone (LD-Dex) in Patients With Relapsed or Refractory Multiple Myeloma
- Conditions
- First Posted Date
- 2012-07-03
- Last Posted Date
- 2019-11-12
- Lead Sponsor
- Celgene
- Registration Number
- NCT01632826
- Locations
- 🇨🇦
Celgene Study Site, Saskatoon, Saskatchewan, Canada
An Investigational Immuno-Therapy Study to Determine the Safety and Effectiveness of Nivolumab and Daratumumab in Patients With Multiple Myeloma
- First Posted Date
- 2012-05-07
- Last Posted Date
- 2024-08-29
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 316
- Registration Number
- NCT01592370
- Locations
- 🇺🇸
Local Institution - 0007, Philadelphia, Pennsylvania, United States
🇺🇸Division Of Hematology & Oncology Ctr. For Health Sciences, Los Angeles, California, United States
🇫🇷Local Institution - 0043, Poitiers, Vienne, France
A Phase I/II Trial of Pomalidomide and Dexamethasone in Subjects With Previously-Treated AL Amyloidosis
- First Posted Date
- 2012-04-04
- Last Posted Date
- 2020-09-22
- Lead Sponsor
- Boston Medical Center
- Target Recruit Count
- 27
- Registration Number
- NCT01570387
- Locations
- 🇺🇸
Boston Medical Center, Boston, Massachusetts, United States
Japanese Phase 1 Study to Evaluate Tolerated Dose, Safety, and Efficacy of Pomalidomide in Patients With Refractory or Relapsed and Refractory Multiple Myeloma
- First Posted Date
- 2012-04-02
- Last Posted Date
- 2019-11-12
- Lead Sponsor
- Celgene
- Target Recruit Count
- 12
- Registration Number
- NCT01568294
- Locations
- 🇯🇵
Nagoya City University Hospital, Nagoya, Aichi, Japan
🇯🇵National Cancer Center Hospital, Tyuuou, Tokyo, Japan
🇯🇵Niigata Cancer Center Hospital, Niigata, Japan
Sotatercept (ACE-011) With Lenalidomide or Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2012-03-23
- Last Posted Date
- 2024-04-18
- Lead Sponsor
- Massachusetts General Hospital
- Target Recruit Count
- 33
- Registration Number
- NCT01562405
- Locations
- 🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States
🇺🇸Emory University, Atlanta, Georgia, United States
🇺🇸Massachusetts General Hosptial, Boston, Massachusetts, United States
Pomalidomide, Dexamethasone and Pegylated Liposomal Doxorubicin for Relapsed/Refractory Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2012-02-29
- Last Posted Date
- 2016-03-10
- Lead Sponsor
- Oncotherapeutics
- Target Recruit Count
- 70
- Registration Number
- NCT01541332
- Locations
- 🇺🇸
Mission Hope Cancer Center, Santa Maria, California, United States
🇺🇸Pacific Cancer Care, Salinas, California, United States
🇺🇸Roy and Patricia Disney Family Cancer Center, Burbank, California, United States
Filgrastim in Treating Patients With Bortezomib-, Carfilzomib-, or IMID-Refractory Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2012-02-23
- Last Posted Date
- 2015-01-26
- Lead Sponsor
- Washington University School of Medicine
- Target Recruit Count
- 7
- Registration Number
- NCT01537861
- Locations
- 🇺🇸
Washington University School of Medicine, St. Louis, Missouri, United States
Study to Determine the Maximum Tolerated Dose, Safety and Effectiveness of Pomalidomide for Patients With Sickle Cell Disease
- First Posted Date
- 2012-01-31
- Last Posted Date
- 2019-11-08
- Lead Sponsor
- Celgene
- Target Recruit Count
- 12
- Registration Number
- NCT01522547
- Locations
- 🇺🇸
Karmanos Cancer Institute, Detroit, Michigan, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.